Milestone Pharmaceuticals Inc. filings document a commercial-stage biopharmaceutical company focused on cardiovascular medicines, including CARDAMYST (etripamil) nasal spray for adults with PSVT. Its 8-K filings report financial results, commercial launch updates, regulatory and corporate updates, Regulation FD presentations and material events related to etripamil.
The filing record also covers Milestone's Nasdaq-listed common shares, proxy governance for annual shareholder meetings, board and voting matters, and capital-structure items such as the completed sale of a royalty interest tied to U.S. etripamil net product sales. These disclosures provide formal records of operating results, governance, financing arrangements and product-related corporate events.
Milestone Pharmaceuticals Inc. filed a report stating that on November 12, 2025 it issued a press release covering its financial results for the third quarter ended September 30, 2025.
The press release also includes a regulatory and corporate update, giving readers insight into recent business and regulatory developments alongside the quarterly numbers. This press release is furnished as Exhibit 99.1 to the report and incorporated by reference, meaning the detailed figures and commentary are contained in that attached document.
Milestone Pharmaceuticals (MIST) filed its Q3 2025 10‑Q. The company reported a net loss of $11.9 million for the quarter and $45.6 million for the nine months. Operating expenses reflected continued R&D and growing commercial preparation, with quarterly R&D of $3.9 million, G&A of $3.3 million, and commercial spend of $4.6 million.
Liquidity strengthened after a July equity and warrant financing, bringing net proceeds of $48.6 million. Cash, cash equivalents and short‑term investments totaled $82.6 million as of September 30, 2025, and management expects liquidity to support operations for at least 12 months. Q3 operating cash outflow was part of year‑to‑date cash used in operations of $36.3 million.
Following a March 2025 Complete Response Letter for CARDAMYST (etripamil) in PSVT, the FDA accepted the company’s resubmission with a PDUFA target date of December 13, 2025. Senior secured convertible notes had a net carrying amount of $56.2 million. Common shares outstanding were 85,169,344 as of September 30, 2025.
Milestone Pharmaceuticals Inc. filed a Form S-8 to register an additional 4,000,000 common shares issuable under its 2019 Equity Incentive Plan, as amended, reflecting shareholder approval of the increase.
The filing incorporates by reference the Registrant's Annual Report for the fiscal year ended December 31, 2024, the Definitive Proxy Statement filed April 30, 2025, Quarterly Reports for the periods ended March 31, 2025 and June 30, 2025, various Current Reports and the Form 8-A description of common stock. Exhibits include amended organizational documents, the amended 2019 EIP, option and RSU award forms, legal opinions and consents.
Milestone Pharmaceuticals reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a regulatory and corporate update. The Form 8-K states the press release is attached as Exhibit 99.1 and is incorporated by reference; the filing text itself does not include the numerical results or detailed financial tables. The 8-K also lists the Interactive XBRL cover page file as Exhibit 104 and identifies the disclosure under the Results of Operations and Financial Condition item. Investors are directed to the attached press release for substantive figures and commentary.
Milestone Pharmaceuticals (MIST) delivered a mixed quarterly update focused on advancing its lead candidate, etripamil, while absorbing higher operating losses. For the six months ended June 30, 2025 the company reported a net loss of $33.7 million (net loss per share $0.51) and an accumulated deficit of $401.3 million. As of June 30, 2025, Milestone held $42.5 million in cash and $0.9 million in short-term investments (total ~$43.4 million) and reported total assets of $47.4 million and total liabilities of $65.2 million, including $55.2 million in senior secured convertible notes.
The FDA issued a Complete Response Letter in March 2025 citing CMC and inspection items but accepted Milestone’s June 13, 2025 response and set a PDUFA target date of December 13, 2025. A July 11, 2025 underwritten offering subsequently provided approximately $48.7 million of net proceeds and the RTW royalty agreement marketing deadline was extended to December 31, 2025. NODE-303 data showed a median time-to-conversion of 17 minutes with generally favorable tolerability. The company reported no revenue for the periods presented.